cp wire

CP Wire Articles

National Comprehensive Cancer Network Releases New Guidelines for Cabometyx for Advanced Renal Cell Carcinoma
  • CABOMETYX is the only preferred tyrosine kinase inhibitor (TKI) treatment option for first-line patients in the poor- and intermediate-risk groups (Category 2A)
  • CABOMETYX is a... read more
Fri, 09/7/18 - 09:44 am
Synthetic Biologics Announces Trial with Cedars-Sinai to Study SYN-010 for the Treatment of IBS-C

Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today... read more

Thu, 09/6/18 - 12:16 pm
Synlogic Reports Positive Interim Ph I/IIa Data for Microbiome Based Treatment for Phenylketonuria

Synlogic, Inc., (Nasdaq:SYBX) a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today announced positive interim clinical data from the healthy... read more

Thu, 09/6/18 - 12:03 pm
Allogene Therapeutics Banks $120 Million in Private Financing
  • Allogene completed a $300 Million Series A round in April of 2018
  • Investors in the Series A round included Gilead and Pfizer


Allogene Therapeutics, Inc., a clinical-... read more

Thu, 09/6/18 - 09:37 am
Vertex Completes Enrollment of Two Ph III Studies of Cystic Fibrosis Drug Combination
  • VX-659 and VX-445 are next gen correctors
  • Correctors fix the defective CFTR protein so that it can move to the proper place on the cell surface
  • Vertex expects to submit an... read more
Thu, 09/6/18 - 09:20 am

Pages